{
    "ticker": "CRGX",
    "name": "CorMedix Inc.",
    "description": "CorMedix Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutic products for the treatment of serious conditions in the fields of infectious disease and cardiovascular health. Founded in 2006 and headquartered in Bridgewater, New Jersey, CorMedix aims to address unmet medical needs through innovative solutions. The company's lead product candidate, DefenCath, is an antimicrobial catheter lock solution designed to prevent catheter-related bloodstream infections in patients with central venous catheters. CorMedix is dedicated to improving patient outcomes and reducing healthcare costs associated with infections. The company has made significant strides in clinical development and regulatory progress, working diligently to bring DefenCath to market, with the goal of enhancing patient safety and quality of life. CorMedix\u2019s mission is to transform the treatment landscape for patients facing serious health challenges by leveraging cutting-edge research and development, as well as strategic partnerships.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Bridgewater, New Jersey, USA",
    "founded": "2006",
    "website": "https://www.cormedix.com",
    "ceo": "Kirk L. M. Van Duyne",
    "social_media": {
        "twitter": "https://twitter.com/CorMedix",
        "linkedin": "https://www.linkedin.com/company/cormedix"
    },
    "investor_relations": "https://www.cormedix.com/investors",
    "key_executives": [
        {
            "name": "Kirk L. M. Van Duyne",
            "position": "CEO"
        },
        {
            "name": "Cynthia A. J. Schreiber",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Products",
            "products": [
                "DefenCath"
            ]
        }
    ],
    "seo": {
        "meta_title": "CorMedix Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore CorMedix Inc., a biopharmaceutical company dedicated to developing innovative therapies for serious medical conditions. Learn about their lead product, DefenCath, aimed at preventing infections.",
        "keywords": [
            "CorMedix",
            "Biopharmaceuticals",
            "Infectious Disease",
            "Cardiovascular Health",
            "DefenCath"
        ]
    },
    "faq": [
        {
            "question": "What is CorMedix known for?",
            "answer": "CorMedix is known for developing DefenCath, an antimicrobial catheter lock solution to prevent infections in patients with central venous catheters."
        },
        {
            "question": "Who is the CEO of CorMedix?",
            "answer": "Kirk L. M. Van Duyne is the CEO of CorMedix Inc."
        },
        {
            "question": "Where is CorMedix headquartered?",
            "answer": "CorMedix is headquartered in Bridgewater, New Jersey, USA."
        },
        {
            "question": "What are CorMedix's main products?",
            "answer": "CorMedix's main product is DefenCath, aimed at reducing catheter-related bloodstream infections."
        },
        {
            "question": "When was CorMedix founded?",
            "answer": "CorMedix was founded in 2006."
        }
    ],
    "competitors": [
        "AMRN",
        "SPPI",
        "RDUS",
        "HRTX"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "ABBV"
    ]
}